Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 45 and 85 years old.
- People who have had a complete prostate MRI scan (a detailed imaging test called mpMRI) with acceptable image quality, showing a suspicious area scored 3 or higher on a standard rating system called PI-RADS V2.1.
- People whose test results meet the standard medical reasons for having a prostate biopsy — for example, a suspicious finding during a physical rectal exam, an unusual result on ultrasound or MRI, or certain PSA blood test levels that fall outside normal ranges (confirm with trial site for exact values).
- People whose test results meet the standard medical reasons for having a repeat prostate biopsy — for example, certain previous biopsy findings, rising PSA levels over time, or other abnormal test results (confirm with trial site for specific criteria); any repeat biopsy must have taken place at least three months after the first.
- People who have complete biopsy results from the suspicious area identified on MRI, taken within one month of the mpMRI scan.
- People who have a complete set of medical records and clinical information available.
Who may not be able to join:
- People whose prostate MRI scan results are incomplete or of poor quality.
- People who received radiotherapy, chemotherapy, hormone therapy, or surgery before their prostate MRI scan or biopsy.
- People whose prostate MRI scan did not show any suspicious areas.
- People whose test results do not meet the standard medical reasons for a prostate biopsy, or who did not receive both a standard biopsy and a targeted biopsy combined.
- People who are unable to cooperate with completing both types of biopsy, or where the patient or their family has declined to take part in the study.
- People who have incomplete medical records or clinical information.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yi LIU, Peking University First Hospital
Phone: +86 13611035261
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The clinically significant prostate cancer (csPCa) detection rate for targeted biopsy (TB) and TB combined with systematic biopsy (SB)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.